211 related articles for article (PubMed ID: 28664940)
1. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
Hao S; Lin P; Medeiros LJ; Fang L; Carballo-Zarate AA; Konoplev SN; Sargent RL; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Lu X
Mod Pathol; 2017 Oct; 30(10):1378-1386. PubMed ID: 28664940
[TBL] [Abstract][Full Text] [Related]
2. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
3. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X
Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554
[TBL] [Abstract][Full Text] [Related]
4. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.
Govindasamy P; Pandurangan P; Tarigopula A; Mani R; R Samuel C
Asian Pac J Cancer Prev; 2019 Jan; 20(1):235-241. PubMed ID: 30678438
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
8. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.
Hamdaoui H; Benlarroubia O; Ait Boujmia OK; Mossafa H; Ouldim K; Belkhayat A; Smyej I; Benrahma H; Dehbi H; Chegdani F
Mol Genet Genomic Med; 2020 Sep; 8(9):e1363. PubMed ID: 32573970
[TBL] [Abstract][Full Text] [Related]
10. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
[TBL] [Abstract][Full Text] [Related]
11. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
12. Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma.
Rabani H; Ziv M; Lavi N; Aviv A; Suriu C; Shalata A; Haddid Y; Tadmor T
Leuk Res; 2020 Dec; 99():106476. PubMed ID: 33171301
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y; Li Q; Xing S; Zhang H; Li D
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
[TBL] [Abstract][Full Text] [Related]
14. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
Sun C; Wang J; Guo HF; Zhou X; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
[TBL] [Abstract][Full Text] [Related]
15. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
16. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and experimental study of a multiple myeloma case with low hypodiploidy].
Bai SX; Pan JL; Xue YQ; Chen SN; Wu YF; Wang Y; Zhang J; Shen J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Jun; 29(3):343-6. PubMed ID: 22678804
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
Shin SY; Eom HS; Sohn JY; Lee H; Park B; Joo J; Jang JH; Lee MN; Kim JK; Kong SY
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):159-164.e2. PubMed ID: 28089441
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biologic implications of recurrent genomic aberrations in myeloma.
Fonseca R; Blood E; Rue M; Harrington D; Oken MM; Kyle RA; Dewald GW; Van Ness B; Van Wier SA; Henderson KJ; Bailey RJ; Greipp PR
Blood; 2003 Jun; 101(11):4569-75. PubMed ID: 12576322
[TBL] [Abstract][Full Text] [Related]
20. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
